Case Study on Analysing the Early Disease Detection of Pancreatic Ductal Adenocarcinoma in Korean Association for Clinical Oncology.
Journal
American journal of clinical oncology
ISSN: 1537-453X
Titre abrégé: Am J Clin Oncol
Pays: United States
ID NLM: 8207754
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
4
7
2024
Statut:
aheadofprint
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is the most pervasive sort of pancreatic malignant growth. Due to the lack of early symptoms and effective methods for early detection and screening, the majority of patients (80% to 85%) are diagnosed with advanced metastatic or locally advanced disease, resulting in a low 5-year survival rate of 12%. The case study represents a comprehensive investigation into the intricate landscape of pancreatic cancer diagnosis within the Korean population. Grounded in epidemiological bits of knowledge, the review plans to disentangle the particular examples, commonness, and segment attributes of PDAC in Korea. By scrutinizing current diagnostic modalities, including conventional imaging techniques, molecular markers, and emerging technologies, the research seeks to evaluate the strengths and limitations of existing approaches within the Korean clinical context. Central to the study is an exploration of the collaborative initiatives spearheaded by the Association of Clinical Oncology in Korea in the domain of PDAC early detection. Analysing research projects, clinical trials, and interdisciplinary collaborations, the case study sheds light on the association's pivotal role in driving innovation and progress in oncology. The goal is to offer a detailed analysis of how the association helps in furthering knowledge and enhancing results in the management of PDAC. The case study delves into the implications of early PDAC detection for patient outcomes, emphasizing the significance of timely interventions and tailored treatment strategies. By outlining the potential benefits and challenges associated with early diagnosis, the study aims to inform health care policies, shape clinical guidelines, and guide future research priorities. Through a holistic approach, the case study endeavours to offer important experiences into the multifaceted landscape of PDAC early detection within the Korean health care system, contributing to the broader discourse on effective oncological practices and patient care.
Identifiants
pubmed: 38963000
doi: 10.1097/COC.0000000000001118
pii: 00000421-990000000-00210
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Kim DW, Lee SS, Kim SO, et al. Estimating recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma by using pancreatic CT: development and validation of a risk score. Radiology. 2020;296:541–551.
Yun WG, Han Y, Cho YJ, et al. In neoadjuvant FOLFIRINOX chemotherapy for pancreatic ductal adenocarcinoma, which response is the more reliable indicator for prognosis, radiologic or biochemical? Ann Surg Oncol. 2024;31:1336–1346.
Kim HS, Choi YH, Jo IH, et al. Tracking incidentally discovered pancreatic cysts smaller than 30 mm: natural course and predictors of malignancy. Dig Liver Dis. 2023;58:137–143.
Zen Y. Autoimmune pancreatitis: biopsy interpretation and differential diagnosis. In: Seminars in Diagnostic Pathology. WB Saunders; 2024.
Kim HS, Han HS, Kim W, et al. Clinical implications of young-onset pancreatic cancer patients after curative resection in Korea: a Korea Tumor Registry System Biliary Pancreas database analysis. HPB. 2023;25:146–154.
Vikash F, Vikash S, Mehta A, et al. Decoding the diagnostic dilemma: Peripheral T‑cell lymphoma presenting as acute pancreatitis: a case report. Oncol Lett. 2024;27:1–5.
Lee B, Yoon YS, Kang M, et al. Validation of the anatomical and biological definitions of borderline resectable pancreatic cancer according to the 2017 international consensus for survival and recurrence in patients with pancreatic ductal adenocarcinoma undergoing upfront surgery. Ann Surg Oncol. 2023;30:3444–3454.
Tsuboi J, Yamada R, Hirokawa YS. Molecular biomarkers in pancreatic ductal adenocarcinoma. Biomarkers in Cancer Detection and Monitoring of Therapeutics. Academic Press; 2024:151–173.
Lee SH, Hwang DW, Yoo C, et al. Survival benefit of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant FOLFIRINOX. Cancer Res Treat. 2023;55:956–968.
Lee SH, Choe JW, Cheon YK, et al. Revised clinical practice guidelines of the korean pancreatobiliary association for acute pancreatitis. Gut Liver. 2023;17:34.
Marcinak CT, Schwartz PB, Basree MM, et al. Treatment of oligometastatic GI cancers. Am Soc Clin Oncol Educ Book. 2024;44:e430152.
Lee DH, Ha HI, Jang JY, et al. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. Eur Radiol. 2023;33:1–11.
Lee JH, Shin J, Min JH, et al. Preoperative prediction of early recurrence in resectable pancreatic cancer integrating clinical, radiologic, and CT radiomics features. Cancer Imaging. 2024;24:6.
Yuk JS, Kim T, Cho H, et al. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study. Eur J Endocrinol. 2024;190:1–11.
Fu C, Zhang B, Guo T, et al. Imaging evaluation of peritoneal metastasis: current and promising techniques. Korean J Radiol. 2024;25:86–102.
Jang SI, Lee HK, Chang EJ, et al. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing. Cancer Immunol Immunother. 2023;72:2757 –2768.
Makler A, Asghar W. Exosomal miRNA biomarker panel for pancreatic ductal adenocarcinoma detection in patient plasma: a pilot study. Int J Mol Sci. 2023;24:5081.
Nené NR, Ney A, Nazarenko T, et al. Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning. Commun Med. 2023;3:10.
Lee DH, Yoon W, Lee A, et al. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Sci. 2023;30:122–132.
Liou GY, Byrd CJ. Diagnostic bioliquid markers for pancreatic cancer: what we have vs. what we need. Cancers. 2023;15:2446.
Zhao R, Ren S, Li C, et al. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Cancer Med. 2023;12:5158–5171.
Yang X, Wang G, Song Y, et al. PD-1+ CD8+ T cells proximal to PD-L1+ CD68+ macrophages are associated with poor prognosis in pancreatic ductal adenocarcinoma patients. Cancers. 2023;15:1389.
Han Y, Drobisch P, Krüger A, et al. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma. J Hematol Oncol. 2023;16:1–19.
Gautam SK, Khan P, Natarajan G, et al. Mucins as potential biomarkers for early detection of cancer. Cancers. 2023;15:1640.
Hyeon DY, Nam D, Han Y, et al. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Nat Cancer. 2023;4:290–307.
Hwang Y-J, Park SM, Ahn S, et al. Accuracy of an administrative database for pancreatic cancer by international classification of disease 10th codes: a retrospective large-cohort study. World J Gastroenterol. 2019;25:5619.
Pang Y, Holmes MV, Chen Z, et al. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2019;34:330–345.
Ko SW, Kim TH, Song TJ, et al. Prognosis and clinical characteristics of patients with pancreatic ductal adenocarcinoma diagnosed by endoscopic ultrasonography but indeterminate on computed tomography. Gut Liver. 2022;16:474.
Nam H, Hong SS, Jung KH, et al. A serum marker for early pancreatic cancer with a possible link to diabetes. J Natl Cancer Inst. 2022;114:228–234.
Matsubayashi H, Ishiwatari H, Sasaki K, et al. Detecting early pancreatic cancer: current problems and future prospects. Gut Liver. 2020;14:30.
Partyka O, Pajewska M, Kwaśniewska D, et al. Overview of pancreatic cancer epidemiology in Europe and Recommendations for Screening in High-Risk populations. Cancers. 2023;15:3634.
Chen PT, Wu T, Wang P, et al. Pancreatic cancer detection on CT scans with deep learning: a nationwide population-based study. Radiology. 2023;306:172–182.
Recouvreux MV, Grenier SF, Zhang Y, et al. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma. Nat Cancer. 2024;5:100–113.